LAW OFFICES
HYMAN, PHELPS & MCNAMARA, P.C.
700 THIRTEENTH STREET, N.W.
SUITE 1200
WASHINGTON, D.C. 20005-5929
(202) 737-5600
FACSIMILE
(202) 737-9329
www.hpm.com

KURT R. KARST

Direct Dial (202) 737-7544
kkarst@hpm.com

March 2, 2021

BY ELECTRONIC SUBMISSION

Division of Dockets Management
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061 (HFA-305)
Rockville, MD 20852

RE: Docket No. FDA-2019-P-1678; Withdrawal

Dear Sir or Madam:

The undersigned, on behalf of Petitioner, Exela Pharma Sciences, LLC, hereby withdraws the Citizen Petition, dated April 5, 2019, requesting that FDA assign a Therapeutic Equivalence Evaluation Code for the company's GLYRX-PF (glycopyrrolate injection), 0.2 mg/mL and 0.4 mg/2 mL, approved under New Drug Application 210997.

Sincerely,



Kurt R. Karst

KRK/eam